Trevi Therapeutics Provides Updates on Haduvio’s Clinical Trials
Trevi Therapeutics, Inc. (NASDAQ: TRVI), a prominent clinical-stage biopharmaceutical firm, has made significant strides in its clinical development program for Haduvio™, an investigational therapy designed to target chronic cough associated with idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC). The latest updates reveal critical milestones in the ongoing trials, which promise to shape the future of treatment for patients grappling with these challenging conditions.
Recent Clinical Milestones
The Phase 2b CORAL trial, aimed at evaluating Haduvio's effectiveness in treating chronic cough for patients with IPF, has hit a notable enrollment milestone, achieving 50% of the targeted participant level. This is essential for conducting the pre-specified sample size re-estimation (SSRE) once the last group of patients completes their six-week treatment regimen. The result of this evaluation is anticipated in December 2024, with three potential outcomes: maintaining the current sample size, increasing the size to fit prescribed parameters, or assessing the trial for futility. If no changes occur, topline results from this study are expected in the first half of 2025.
Human Abuse Potential Study
Another noteworthy advancement is the completion of dosing in the Human Abuse Potential (HAP) study, with topline results also expected later in December 2024. The HAP study is crucial to gauge the safety profile of Haduvio and its implications for patients utilizing the medication.
Further Trial Developments
Simultaneously, in the Phase 2a RIVER trial for treatment of RCC, all intended participants have been enrolled, though the trial will remain open for additional enrollments in both recruitment arms to better meet stratification targets. Topline results from this initiative are now projected for the first quarter of 2025.
About Haduvio and Its Mechanism
Haduvio™ is an extended-release formulation of oral nalbuphine, which functions as a dual ????-opioid receptor agonist and ????-opioid receptor antagonist. This unique mechanism allows Haduvio to engage both centrally within the brain and peripherally in the lungs, aiming to develop a synergistic effect for alleviating chronic cough symptoms. This anatomical approach positions Haduvio as a pivotal development in addressing chronic cough, particularly in patients who have yet to find relief through existing treatments.
The Importance of Treating Chronic Cough
Chronic cough significantly impacts patients' quality of life, often leading to social, physical, and psychological challenges. For individuals with IPF, a persistent cough can exacerbate their condition, potentially increasing the risk of disease progression and necessitating critical interventions such as lung transplants. Current therapies available offer scant relief, emphasizing the pressing need for effective medications. Up to 10% of the adult population suffers from chronic cough, illustrating the broad scope of Haduvio's potential market — especially as it explores options to treat RCC, a condition that currently lacks approved therapies in the United States.
Trevi’s Long-term Vision
Trevi Therapeutics is dedicated to advancing Haduvio as a mainstream trade name for oral nalbuphine ER. However, it is essential to note that the safety and effectiveness of Haduvio have yet to receive evaluation from any regulatory authority. The company remains focused on addressing the unmet needs of patients and providing much-needed innovation in the biopharmaceutical space.
Frequently Asked Questions
What is Haduvio?
Haduvio is an investigational therapy being developed by Trevi Therapeutics aimed at treating chronic cough associated with IPF and RCC.
How is the Phase 2b CORAL trial progressing?
The trial has reached 50% of its enrollment goal, with expected results from the sample size re-estimation coming in December 2024.
What are the potential benefits of Haduvio?
Haduvio could provide a dual-action treatment for chronic cough, addressing both central and peripheral pathways to suppress cough reflex effectively.
When can we expect results from the HAP study?
Topline results from the Human Abuse Potential study are anticipated in December 2024.
Why is chronic cough a concern for IPF patients?
A chronic cough can worsen the overall condition of IPF patients and dramatically affect their quality of life, highlighting the need for effective treatments.
